Strata's Q2 Numbers Say the Old Blade Story Is Over

The market still thinks of Blade Air Mobility as a loss-making helicopter charter company that gave up on passenger rides and changed its name. Strata Critical Medical (SRTA) is not that company anymore. The Q2 results and the guidance raise it attached tell a different story: a lean medical logistics operator that is already growing revenue at 60% and expanding margins, with free cash flow finally showing up.

SRTA's stock was up 10.6% in morning trading on Wednesday, moving from $5.02 to $5.55. That reaction is warranted, but the question is whether the rerating has legs.

The old story

Until August 2025, Blade was a mixed-bag air mobility platform - consumer helicopter charters and medical organ transport bundled together under one ticker. The passenger side was capital-intensive and thin-margin. The medical side was growing fast and pulling more of the EBITDA but kept getting overshadowed by the consumer brand. Management sold the Passenger division to Joby Aviation for up to $125 million, rebranded the remaining business as Strata Critical Medical, and changed the ticker to SRTA. A clean break.

What the numbers actually show

Q2 2026 revenue hit $72.5 million, up 60.7% year-over-year from $45.1 million. That is not a surprise move - the year-ago comparison includes the addition of the Clinical business (acquired as Keystone Perfusion in Q3 2025) and three bolt-on acquisitions closed in Q2. But the sequential number is the one that matters. Clinical revenue grew 15.1% quarter-over-quarter on an organic basis, excluding the Q2 acquisitions. Transplant Clinical revenue, the highest-margin wedge, grew 23.8% sequentially.

Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization - the closest non-GAAP proxy to operating cash generation) was $7.9 million, or 10.9% of revenue. That is up from 9.5% in Q1 2026. Gross margin across the business sat at 21.0%, with Logistics at 18.4% and the Clinical mix pulling the average higher. The margin trajectory is the proof point: each quarter the business shifts toward the higher-margin Clinical services, and the numbers confirm it.

Free cash flow was $2.9 million in Q2, with operating cash flow at $5.7 million. Both are company records. The gap between Adjusted EBITDA and operating cash flow was $2.2 million, driven by working capital timing - a temporary drag, not a structural problem.

GAAP net loss of $10.5 million looks ugly on the surface. About $5 million of that was accelerated trademark amortization from the rebrand, and another $10.5 million swing came from non-cash revaluation of transaction earn-out liabilities. Strip those out and the operating story is the one that matters.

The guidance raise is the signal

This is the part that should change how you think about the next 12 months. Management raised full-year 2026 revenue guidance to $285–295 million, up from $260–275 million. That is roughly a 10% midpoint increase. Adjusted EBITDA guidance moved to $33–35 million from $29–33 million - also a roughly 12% midpoint lift. Free cash flow guidance before aircraft and engine acquisitions was reaffirmed at $15–22 million.

Pro forma for all 2026 acquisitions, revenue would be $295–305 million. The raise came after Q4 2025 already beat the high end of the prior guidance. Two consecutive quarters of beating expectations, followed by a raise, is not noise.

M&A at the right price

The three bolt-on acquisitions in Q2 - Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program, and Ohio Valley Perfusion Associates - add more than $6 million of projected annualized Adjusted EBITDA at mid-single-digit multiples. Management has been clear about the discipline: no overpaying, bolt-ons that integrate into existing operations, and a target of accelerating annualized Adjusted EBITDA growth by at least 30% per year through M&A. The Statline Transplant Center Organ Placement agreement, which rolls in customer relationships over the next 12 months, extends the pipeline without a large upfront check.

This is how a platform company actually compounds. Acquire at low multiples, integrate into a shared logistics and clinical network, cross-sell, and let the higher-margin Clinical mix do the rest.

Where the market is still anchored

Four analysts cover the stock, with an average 12-month target of $9.25 against the current $5.02 price. That implies 84% upside on average. GuruFocus's GF Value model sits at $4.88, just below the current price, which means a DCF-style approach using generic growth and discount assumptions doesn't see the rerating. That's because the GF model does not capture the step-change in growth rate and margin trajectory that the guidance raise confirms.

The market is pricing a business that hasn't yet proved its new identity. The guidance raise, the margin expansion, and the free cash flow record say otherwise.

The risks are real

The cash balance is thin: $22.8 million at the end of Q2, down from $113.4 million at the end of Q2 2025. That drawdown reflects the Passenger sale proceeds being deployed into Clinical acquisitions and the build-out of a higher-quality fleet. It means Strata has limited runway for a large unscheduled acquisition or a sustained operational hit. If a material customer relationship sours, or an acquisition integrates poorly, the cash position could become a constraint.

The GAAP loss rate of 14.5% of revenue, even before non-cash items, is a reminder that the business is not yet cash-flow profitable on a full annualized basis. The $15–22 million free cash flow guidance for 2026 is solid but not huge. Any delay in the Clinical mix shift would compress margins.

The setup

The market is still pricing the old Blade risk profile. The numbers say the new business is already running faster and more profitably than the guidance from a year ago projected. Revenue accelerating toward the high end of $290 million, Adjusted EBITDA expanding toward $34 million, and free cash flow holding above $15 million - that's the bridge.

The analyst average target of $9.25 is the simplest way to frame the upside without reaching for a spreadsheet. If SRTA delivers at the midpoint of its own raised guidance, a stock that trades around $5 today has a credible path to a meaningful rerating. The tripwire is the reverse: if the Clinical mix stalls, Adjusted EBITDA margins fall back toward single digits, or free cash flow turns negative in back-to-back quarters, the inflection thesis breaks. Discipline over ego.

The entry is clean because expectations have already reset. The passenger business is gone. The name has changed. The cash burn is real but directed. The only question left is whether the operating team continues to execute the plan they're already ahead of.